菜单

Speed Redefined:
6 Months from DNA to IND

Get from DNA to IND in only 6 months. Exclusive to WuXi Biologics, this accelerated timeline compresses development costs, de-risks programs, and delivers a decisive competitive edge. A fully integrated, single-source model orchestrates all CMC and IND-enabling activities, eliminating third-party bottlenecks within a robust, quality-first infrastructure.

A track record of reliability:
over 65 INDs delivered within 6 months.

Ready to Cut Your Time to Clinic?

Talk to Our Expert

Cut Timelines, Not Quality

WuXi Biologics’ DNA-to-IND timeline prioritizes not only speed, but a strong foundation for clinical progression. Our integrated approach ensures accelerated timelines remain aligned with quality and data integrity. Together, these strengths drive 3 core strategies that systematically build a regulatory-ready package designed for a successful IND submission.

Proprietary Platform Technology

The WuXia™ CHO-K1 platform harmonizes cell line development, process development, and GMP manufacturing. This single, standardized engine establishes a deep, foundational understanding of your product from the start, streamlining every transition and delivering consistent, high-titer performance.

Commercially Aligned Process Development

Consistent, pre-qualified materials and methods feed strategic alignment from early development through commercial scale-up. Our approach eliminates time-consuming redevelopment, fuels operational efficiency, and generates a regulatory-ready data package for IND.

Centralized Program Management

A dedicated, single-point program management team guides each program with precision and transparency. Simplified communication and alignment across all cross-functional experts maintains continuity of data and decision-making, significantly lowering your risk of candidate attrition.

Your Program, Accelerated

Six months represents a new standard for monoclonal antibodies. For more complex modalities, WuXi Biologics offers the flexibility of a 10-month path. All projects are preset for regulatory compliance and seamless scale-up, setting up successful entry into clinical trials.

CMC rigor allows WuXi Biologics to outperform the standard timeline of 12 months by at least 2 months. More than a theoretical achievement, our track record supports this acceleration.